Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 4Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2CNS 1Breast 1

Conditions

Colorectal Neoplasms 10Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Unresectable Metastatic Colorectal Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Margins of Excision 1Kidney Neoplasms 1Histiocytosis 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1

Interventions

Oxaliplatin 42Fluorouracil 27Capecitabine 24pembrolizumab 21S 1 (combination) 19Paclitaxel 19Leucovorin 16Nivolumab 13sintilimab 12Drug Therapy 12Docetaxel 12tislelizumab 11Trastuzumab 10Cisplatin 10Irinotecan 8Bevacizumab 8trastuzumab deruxtecan 7spartalizumab 7fludarabine 7XELOX 7Surgical Procedures, Operative 7Radiotherapy 7Cyclophosphamide 7Biopsy 7disitamab vedotin 6Hyperthermic Intraperitoneal Chemotherapy 6lenvatinib 5apatinib 5Specimen Handling 5Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Stomach Neoplasms × IFL protocol × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡